Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma

Raymond G. Fox, Nikki K. Lytle, Dawn V. Jaquish, Frederick D. Park, Takahiro Ito, Jeevisha Bajaj, Claire S. Koechlein, Bryan Zimdahl, Masato Yano, Janel L. Kopp, Marcie Kritzik, Jason K. Sicklick, Maike Sander, Paul M. Grandgenett, Michael A. Hollingsworth, Shinsuke Shibata, Donald Pizzo, Mark A. Valasek, Roman Sasik, Miriam ScadengHideyuki Okano, Youngsoo Kim, A. Robert Macleod, Andrew M. Lowy, Tannishtha Reya

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Pancreatic intraepithelial neoplasia is a pre-malignant lesion that can progress to pancreatic ductal adenocarcinoma, a highly lethal malignancy marked by its late stage at clinical presentation and profound drug resistance. The genomic alterations that commonly occur in pancreatic cancer include activation of KRAS2 and inactivation of p53 and SMAD4 (refs 2, 3, 4). So far, however, it has been challenging to target these pathways therapeutically; thus the search for other key mediators of pancreatic cancer growth remains an important endeavour. Here we show that the stem cell determinant Musashi (Msi) is a critical element of pancreatic cancer progression both in genetic models and in patient-derived xenografts. Specifically, we developed Msi reporter mice that allowed image-based tracking of stem cell signals within cancers, revealing that Msi expression rises as pancreatic intraepithelial neoplasia progresses to adenocarcinoma, and that Msi-expressing cells are key drivers of pancreatic cancer: They preferentially harbour the capacity to propagate adenocarcinoma, are enriched in circulating tumour cells, and are markedly drug resistant. This population could be effectively targeted by deletion of either Msi1 or Msi2, which led to a striking defect in the progression of pancreatic intraepithelial neoplasia to adenocarcinoma and an improvement in overall survival. Msi inhibition also blocked the growth of primary patient-derived tumours, suggesting that this signal is required for human disease. To define the translational potential of this work we developed antisense oligonucleotides against Msi; these showed reliable tumour penetration, uptake and target inhibition, and effectively blocked pancreatic cancer growth. Collectively, these studies highlight Msi reporters as a unique tool to identify therapy resistance, and define Msi signalling as a central regulator of pancreatic cancer.

Original languageEnglish
Pages (from-to)407-411
Number of pages5
JournalNature
Volume534
Issue number7607
DOIs
Publication statusPublished - 2016 Jun 6
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Adenocarcinoma
Neoplasms
Therapeutics
Stem Cells
Growth
Circulating Neoplastic Cells
Antisense Oligonucleotides
Genetic Models
Drug Resistance
Heterografts
Survival
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Medicine(all)
  • General

Cite this

Fox, R. G., Lytle, N. K., Jaquish, D. V., Park, F. D., Ito, T., Bajaj, J., ... Reya, T. (2016). Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma. Nature, 534(7607), 407-411. https://doi.org/10.1038/nature17988

Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma. / Fox, Raymond G.; Lytle, Nikki K.; Jaquish, Dawn V.; Park, Frederick D.; Ito, Takahiro; Bajaj, Jeevisha; Koechlein, Claire S.; Zimdahl, Bryan; Yano, Masato; Kopp, Janel L.; Kritzik, Marcie; Sicklick, Jason K.; Sander, Maike; Grandgenett, Paul M.; Hollingsworth, Michael A.; Shibata, Shinsuke; Pizzo, Donald; Valasek, Mark A.; Sasik, Roman; Scadeng, Miriam; Okano, Hideyuki; Kim, Youngsoo; Macleod, A. Robert; Lowy, Andrew M.; Reya, Tannishtha.

In: Nature, Vol. 534, No. 7607, 06.06.2016, p. 407-411.

Research output: Contribution to journalArticle

Fox, RG, Lytle, NK, Jaquish, DV, Park, FD, Ito, T, Bajaj, J, Koechlein, CS, Zimdahl, B, Yano, M, Kopp, JL, Kritzik, M, Sicklick, JK, Sander, M, Grandgenett, PM, Hollingsworth, MA, Shibata, S, Pizzo, D, Valasek, MA, Sasik, R, Scadeng, M, Okano, H, Kim, Y, Macleod, AR, Lowy, AM & Reya, T 2016, 'Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma', Nature, vol. 534, no. 7607, pp. 407-411. https://doi.org/10.1038/nature17988
Fox RG, Lytle NK, Jaquish DV, Park FD, Ito T, Bajaj J et al. Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma. Nature. 2016 Jun 6;534(7607):407-411. https://doi.org/10.1038/nature17988
Fox, Raymond G. ; Lytle, Nikki K. ; Jaquish, Dawn V. ; Park, Frederick D. ; Ito, Takahiro ; Bajaj, Jeevisha ; Koechlein, Claire S. ; Zimdahl, Bryan ; Yano, Masato ; Kopp, Janel L. ; Kritzik, Marcie ; Sicklick, Jason K. ; Sander, Maike ; Grandgenett, Paul M. ; Hollingsworth, Michael A. ; Shibata, Shinsuke ; Pizzo, Donald ; Valasek, Mark A. ; Sasik, Roman ; Scadeng, Miriam ; Okano, Hideyuki ; Kim, Youngsoo ; Macleod, A. Robert ; Lowy, Andrew M. ; Reya, Tannishtha. / Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma. In: Nature. 2016 ; Vol. 534, No. 7607. pp. 407-411.
@article{378edcf1c22b4602999c1eec4d65e25d,
title = "Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma",
abstract = "Pancreatic intraepithelial neoplasia is a pre-malignant lesion that can progress to pancreatic ductal adenocarcinoma, a highly lethal malignancy marked by its late stage at clinical presentation and profound drug resistance. The genomic alterations that commonly occur in pancreatic cancer include activation of KRAS2 and inactivation of p53 and SMAD4 (refs 2, 3, 4). So far, however, it has been challenging to target these pathways therapeutically; thus the search for other key mediators of pancreatic cancer growth remains an important endeavour. Here we show that the stem cell determinant Musashi (Msi) is a critical element of pancreatic cancer progression both in genetic models and in patient-derived xenografts. Specifically, we developed Msi reporter mice that allowed image-based tracking of stem cell signals within cancers, revealing that Msi expression rises as pancreatic intraepithelial neoplasia progresses to adenocarcinoma, and that Msi-expressing cells are key drivers of pancreatic cancer: They preferentially harbour the capacity to propagate adenocarcinoma, are enriched in circulating tumour cells, and are markedly drug resistant. This population could be effectively targeted by deletion of either Msi1 or Msi2, which led to a striking defect in the progression of pancreatic intraepithelial neoplasia to adenocarcinoma and an improvement in overall survival. Msi inhibition also blocked the growth of primary patient-derived tumours, suggesting that this signal is required for human disease. To define the translational potential of this work we developed antisense oligonucleotides against Msi; these showed reliable tumour penetration, uptake and target inhibition, and effectively blocked pancreatic cancer growth. Collectively, these studies highlight Msi reporters as a unique tool to identify therapy resistance, and define Msi signalling as a central regulator of pancreatic cancer.",
author = "Fox, {Raymond G.} and Lytle, {Nikki K.} and Jaquish, {Dawn V.} and Park, {Frederick D.} and Takahiro Ito and Jeevisha Bajaj and Koechlein, {Claire S.} and Bryan Zimdahl and Masato Yano and Kopp, {Janel L.} and Marcie Kritzik and Sicklick, {Jason K.} and Maike Sander and Grandgenett, {Paul M.} and Hollingsworth, {Michael A.} and Shinsuke Shibata and Donald Pizzo and Valasek, {Mark A.} and Roman Sasik and Miriam Scadeng and Hideyuki Okano and Youngsoo Kim and Macleod, {A. Robert} and Lowy, {Andrew M.} and Tannishtha Reya",
year = "2016",
month = "6",
day = "6",
doi = "10.1038/nature17988",
language = "English",
volume = "534",
pages = "407--411",
journal = "Nature Cell Biology",
issn = "1465-7392",
publisher = "Nature Publishing Group",
number = "7607",

}

TY - JOUR

T1 - Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma

AU - Fox, Raymond G.

AU - Lytle, Nikki K.

AU - Jaquish, Dawn V.

AU - Park, Frederick D.

AU - Ito, Takahiro

AU - Bajaj, Jeevisha

AU - Koechlein, Claire S.

AU - Zimdahl, Bryan

AU - Yano, Masato

AU - Kopp, Janel L.

AU - Kritzik, Marcie

AU - Sicklick, Jason K.

AU - Sander, Maike

AU - Grandgenett, Paul M.

AU - Hollingsworth, Michael A.

AU - Shibata, Shinsuke

AU - Pizzo, Donald

AU - Valasek, Mark A.

AU - Sasik, Roman

AU - Scadeng, Miriam

AU - Okano, Hideyuki

AU - Kim, Youngsoo

AU - Macleod, A. Robert

AU - Lowy, Andrew M.

AU - Reya, Tannishtha

PY - 2016/6/6

Y1 - 2016/6/6

N2 - Pancreatic intraepithelial neoplasia is a pre-malignant lesion that can progress to pancreatic ductal adenocarcinoma, a highly lethal malignancy marked by its late stage at clinical presentation and profound drug resistance. The genomic alterations that commonly occur in pancreatic cancer include activation of KRAS2 and inactivation of p53 and SMAD4 (refs 2, 3, 4). So far, however, it has been challenging to target these pathways therapeutically; thus the search for other key mediators of pancreatic cancer growth remains an important endeavour. Here we show that the stem cell determinant Musashi (Msi) is a critical element of pancreatic cancer progression both in genetic models and in patient-derived xenografts. Specifically, we developed Msi reporter mice that allowed image-based tracking of stem cell signals within cancers, revealing that Msi expression rises as pancreatic intraepithelial neoplasia progresses to adenocarcinoma, and that Msi-expressing cells are key drivers of pancreatic cancer: They preferentially harbour the capacity to propagate adenocarcinoma, are enriched in circulating tumour cells, and are markedly drug resistant. This population could be effectively targeted by deletion of either Msi1 or Msi2, which led to a striking defect in the progression of pancreatic intraepithelial neoplasia to adenocarcinoma and an improvement in overall survival. Msi inhibition also blocked the growth of primary patient-derived tumours, suggesting that this signal is required for human disease. To define the translational potential of this work we developed antisense oligonucleotides against Msi; these showed reliable tumour penetration, uptake and target inhibition, and effectively blocked pancreatic cancer growth. Collectively, these studies highlight Msi reporters as a unique tool to identify therapy resistance, and define Msi signalling as a central regulator of pancreatic cancer.

AB - Pancreatic intraepithelial neoplasia is a pre-malignant lesion that can progress to pancreatic ductal adenocarcinoma, a highly lethal malignancy marked by its late stage at clinical presentation and profound drug resistance. The genomic alterations that commonly occur in pancreatic cancer include activation of KRAS2 and inactivation of p53 and SMAD4 (refs 2, 3, 4). So far, however, it has been challenging to target these pathways therapeutically; thus the search for other key mediators of pancreatic cancer growth remains an important endeavour. Here we show that the stem cell determinant Musashi (Msi) is a critical element of pancreatic cancer progression both in genetic models and in patient-derived xenografts. Specifically, we developed Msi reporter mice that allowed image-based tracking of stem cell signals within cancers, revealing that Msi expression rises as pancreatic intraepithelial neoplasia progresses to adenocarcinoma, and that Msi-expressing cells are key drivers of pancreatic cancer: They preferentially harbour the capacity to propagate adenocarcinoma, are enriched in circulating tumour cells, and are markedly drug resistant. This population could be effectively targeted by deletion of either Msi1 or Msi2, which led to a striking defect in the progression of pancreatic intraepithelial neoplasia to adenocarcinoma and an improvement in overall survival. Msi inhibition also blocked the growth of primary patient-derived tumours, suggesting that this signal is required for human disease. To define the translational potential of this work we developed antisense oligonucleotides against Msi; these showed reliable tumour penetration, uptake and target inhibition, and effectively blocked pancreatic cancer growth. Collectively, these studies highlight Msi reporters as a unique tool to identify therapy resistance, and define Msi signalling as a central regulator of pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=84976328190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976328190&partnerID=8YFLogxK

U2 - 10.1038/nature17988

DO - 10.1038/nature17988

M3 - Article

C2 - 27281208

AN - SCOPUS:84976328190

VL - 534

SP - 407

EP - 411

JO - Nature Cell Biology

JF - Nature Cell Biology

SN - 1465-7392

IS - 7607

ER -